Low Float Biotech (Nasdaq: PALI) Expects Topline Data From Key UC Study In 1st Half Of 2025

In the volatile world of small-cap biotechs, being prepared and informed is critical.

*Sponsored StockWireNews Low Float Biotech (Nasdaq: PALI) Expects Topline Data From Key UC Study In 1st Half Of 2025 March 11th Greetings Readers, In the volatile world of small-cap biotechs, being prepared and informed is critical. And with my newest Nasdaq biotech breakout idea, there's four immediate points to consider: Limited (Low) Float: The profile in question has a notably low public float under 2Mn shares, which could lead to increased volatility on a daily basis. When a supply is limited like this, potential news in the future with positive sentiment could have an outsized impact in the near/short term. Recent Operational Developments: The profile has been making strategic moves in its operations, including potential expansion of manufacturing capabilities and exploring new therapeutic areas. These developments could be pivotal in determining the company's future trajectory. Sector Dynamics: The biotech industry is currently facing challenges, including rising costs and regulatory pressures. However, it's also seeing increased in-vest-ment in innovative technologies and treatments, which could benefit well-positioned companies. Analyst Targets: The most recent consensus from industry analysts indicates a significant triple-digit potential upside. These ambitious targets reflect analysts' optimism about the company's future prospects. With topline data expected in the 1st half of 2025, it may be the perfect time to take a deep-dive into this breakout idea: *Palisade Bio, Inc. (Nasdaq: PALI)* Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. And based on several potential catalysts, PALI has topped my watchlist this week. Check them out: No. 1 - Could A Low Float Create A Volatile Situation In A Blink? No. 2 - Positive Preclinical Data Signals PALI-2108 Heading In The Right Direction. No. 3 - A Potential Upside Over 1,500% To An Analyst $14 Target? No. 4 - Palisade Announces Receipt Of CAD$1.39Mn As Reimbursement Of Prior Pre-Clinical Costs. But more on those in a second... Company Breakdown - Palisade Bio, Inc. Palisade Bio's lead program, PALI-2108, is a microbiota-activated PDE4 inhibitor prodrug in development for the treatment of moderate-to-severe ulcerative colitis. Ulcerative colitis presents a significant challenge for patients, who require therapies that provide effective remission rates, are non-immunosuppressive, and have improved safety profiles. The company employs advanced machine learning to identify patients with elevated PDE4 activity, aiming to enhance the responder population in their lead program targeting ulcerative colitis. By pinpointing key markers of colitis through RNA sequencing and meta-analysis, they identify top PDE4-effector genes, enabling them to predict potential patient responses to PDE4 inhibitors and potentially ensure targeted, effective treatment. Palisade Bio's platform technology provides the opp. to expand their pipeline across immune, inflammatory, and fibrotic diseases. This includes their program, PALI-1908, which is in preclinical development for fibrostenotic Crohn's Disease and has multiple synergies with their lead PALI-2108 program. Development Pipeline Differentiated product candidates with potential to address shortcomings of existing therapies in established markets:

Upcoming Milestones (*Estimated)

PALI-2108 - A Differentiated Approach to Ulcerative Colitis Key Differentiation: Oral Dosing Gut-restricted prodrug is bioactivated locally in the colon resulting in a longer apparent half-life and greater exposure Greater colonic tissue and lesser systemic exposure due to local bioactivation with the potential for greater efficacy and an improved safety profile Demonstrated proof-of-concept efficacy Preclinical and ex vivo data suggest potential for superior efficacy and derisks program Current Therapies for UC - Limited Efficacy with Significant Safety Concerns Though the number of available therapeutics for moderate-to-severe patients is growing, the placebo-adjusted remission rate remains low, ~10-20%, and many therapies have poor safety profiles. Absolute and Placebo-Adjusted Remission Rates at Completion of Induction (8 to 12 Weeks)

Grab Sources: PALI Website. PALI Presentation. ----- As mentioned above, (Nasdaq: PALI) has multiple potential catalysts to consider right now. Take a look: No. 1 PALI Potential Catalyst - Could A Low Float Create A Volatile Situation In A Blink? According to info from the Yahoo Finance website, PALI has a very low float. In fact, the website reports this profile to have approx. 1.18Mn shares in its float. Why is that important? It's important on one crucial level. Volatility potential. Could more positive company news in the first half of 2025 provide a near term spark? ----- No. 2 PALI Potential Catalyst - Positive Preclinical Data Signals PALI-2108 Heading In The Right Direction. Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis From the article: "UC patients need new oral therapies with higher remission rates, less systemic immunosuppression, and a strong safety profile. We continue to be encouraged by our preclinical and clinical results for PALI-2108, and we believe PALI-2108 could be an important option for these patients," said Mitch Jones, MD, Ph.D., Chief Medical Officer of Palisade Bio. "We are on track to report topline data in the first half of 2025 and are excited to continue exploring this novel, oral, intestinally activated PDE4 inhibitor." ----- No. 3 PALI Potential Catalyst - A Potential Upside Over 1,500% To An Analyst $14 Target? Analysts at Ladenburg Thalmann Co. Inc.—a firm with NYSE membership since 1879—published a report mentioning Palisade Bio, Inc. (Nasdaq: PALI). Ladenburg is a diversified financial services company with a history in in-vest-ment banking, equity research, institutional sales and trading, brokerage services, asset management, and trust services. Setting a $14 target for PALI, these analysts may be suggesting that this Nasdaq profile is undervalued at current levels. In fact, from PALI's opening valuation of $.8425 on Tuesday, there may be as much as 1,500+% potential upside. That's massive... ----- No. 4 PALI Potential Catalyst - Palisade Announces Receipt Of CAD$1.39Mn As Reimbursement Of Prior Pre-Clinical Costs. Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC) Company through its co-development partner, Giiant Pharma, Inc. ("Giiant"), receives funding from Canadian Scientific Research and Experimental Development (SR&ED) Tax Credit Program for PALI-2108 Ongoing progress of Palisade Bio's Phase 1a/b UC study of PALI-2108 with topline data expected in the first half of 2025 Carlsbad, CA, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) ("Palisade", "Palisade Bio", or the "Company"), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced the receipt of CAD$1.39Mn Canadian SR&ED credits for reimbursement of prior pre-clinical costs for PALI-2108 incurred under the company's joint development plan with Giiant. "This non-dilutive funding, which resulted from our pre-clinical studies previously conducted in Montreal under our co-development agreement with Giiant, bolsters our efforts to potentially bring a solution to patients," said JD Finley, Chief Executive Officer of Palisade Bio, "We are pleased with the continued progress made with our PALI-2108 program and look forward to reporting topline data in the first half of 2025 from our ongoing Phase 1a/b study." ... Read the full article here. ----- (Nasdaq: PALI) Potential Catalysts Recap - What To Know Now No. 1 - Could A Low Float Create A Volatile Situation In A Blink? No. 2 - Positive Preclinical Data Signals PALI-2108 Heading In The Right Direction. No. 3 - A Potential Upside Over 1,500% To An Analyst $14 Target? No. 4 - Palisade Announces Receipt Of CAD$1.39Mn As Reimbursement Of Prior Pre-Clinical Costs. ----- Coverage is officially initiated on Palisade Bio, Inc. (Nasdaq: PALI). When updates are available, you'll have them quickly. Talk again shortly. Sincerely, Kai Parker StockWireNews (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)

StockWireNews.com ("StockWireNews" or "SWN" ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 03/11/2025 and ending on 03/14/2025 to publicly disseminate information about (PALI:US) via digital communications. Under this agreement, SWN Media LLC has been paid seventeen thousand five hundred USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither SWN Media LLC, TD Media LLC and their member own shares of (PALI:US). Please see important disclosure information here: https://stockwirenews.com/disclosure/pali/#details Unsubscribe Stock Wire News 160 West Camino Real Unit 886 Boca Raton, Florida 33432 United States